Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.35 |
| ▸ | GSK3B | P49841 | 13/20 | 0.35 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607919 | 0.93 | DYRK1A (0.34) | ABL1DYRK1AGSK3BWNT1 | |
| SCHEMBL10278364 | 0.89 | ABL1 (0.34) | ABL1 | |
| SCHEMBL4344353 | 0.89 | MET (0.32) | ABL1DYRK1AGSK3BWNT1 | |
| SCHEMBL4346944 | 0.88 | ITGB3 (0.31) | ABL1 | |
| SCHEMBL2725885 | 0.87 | DYRK1A (0.34) | ABL1DYRK1AGSK3BWNT1NTRK1 | |
| SCHEMBL2728456 | 0.87 | CCKBR (0.33) | ABL1DDR1DDR2DYRK1AGSK3B | |
| SCHEMBL2838079 | 0.86 | GSK3B (0.31) | DYRK1AGSK3B | |
| SCHEMBL212678 | 0.86 | GPR119 (0.38) | DYRK1AGSK3BWNT1 | |
| SCHEMBL212139 | 0.86 | DYRK1A (0.34) | ABL1DYRK1AGSK3BWNT1NTRK1 | |
| SCHEMBL212140 | 0.86 | DYRK1A (0.34) | ABL1DYRK1AGSK3BWNT1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ABL1 956/4885DDR1 2680/4885DDR2 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.